Conditions: Hypertension, Pulmonary
Keywords: sitaxentan sodium pulmonary hypertension
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 2
Healthy volunteers: no

Brief summary:
The safety and efficacy at 100 mg once daily for oral dose of sitaxentan sodium were demonstrated in the STRIDE clinical trial program. Sitaxentan sodium was approved in the EU, Canada and Australia. In this study, the long-term safety and efficacy after administrations of sitaxentan sodium at a dose of 100 mg alone or in combination with another medication will be investigated in Japanese PAH patients.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Sitaxentan
Intervention descriptions: intervention 1: sitaxentan sodium 100 mg

Protocol document: